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A B S T R A C TBackground: Pneumococcal infection is an important and preventable
cause of morbidity and mortality. The Turkish government introduced
7-valent pneumococcal conjugate vaccine (PCV) into the national
immunization program in 2009. This suggests that replacing 7-valent
PCV with a higher-valent version could at least maintain “standard of
care” if not improve it, and that it could be affordable. Objectives and
Methods: The aim of this analysis was to assess the potential direct
cost-effectiveness of 13-valent PCV in Turkey, a country with a birth
cohort of 1.4 million, against a “no vaccine” state, against the default 7-
valent PCV state, and against a 10-valent PCV state, using a publishedsee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.03.1632
sh@imperial.ac.uk.
ndence to: E. David G. McIntosh, UMO, Imperial Cocohort model with a 5-year horizon. Results and Conclusions: The cost
per life-year gained is below the 1  per-capita gross domestic product
threshold across large changes in key input parameters, indicating that
the model is stable and suggesting that any PCV would be very cost-
effective in a Turkish national pediatric immunization schedule.
Keywords: burden of disease, children, cost-effectiveness, pneumonia,
vaccines.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Methods
The Model
Details of the model have been published previously [1]. The
inputs are shown in Table 1 [2,4,6–10]. At all opportunities, we
have erred toward a conservative utilization of the inputs. For
comparison, UK inputs are also shown [1].
Burden of Disease
The epidemiological data used in the model are derived from a
study of 12 Istanbul hospitals [2], which cover 65% of the overall
Istanbul population of 13 million. This, in turn, represents 19% of
the overall Turkish population of 70 million.
The annualized rate of pneumococcal meningitis in children
younger than 5 years is between 3 and 5 per 100,000, for
pneumococcal septicemia 7.5 to 22.5 per 100,000, for hospitalized
(average 6 days) and community suspected pneumococcal pneu-
monia between 210 and 2790 per 100,000, for all-cause otitis media
330 per 1000, and for pneumococcal otitis media 58 per 1000.
Vaccine Efﬁcacy
The efﬁcacy of 7-valent pneumococcal conjugate vaccine (PCV)
and of 13-valent PCV against invasive pneumococcal disease
(IPD) was assumed to be at the lower end of the 95% conﬁdenceinterval (83%) [4], for suspected pneumococcal pneumonia 20.5%
[6], and for all-cause otitis media 6% [7]. The efﬁcacy of 10-valent
PCV against IPD was assumed to be at the lower end of the 95%
conﬁdence interval (83%) [5]. Its efﬁcacy for suspected pneumo-
coccal pneumonia was assumed to be 20.5% and for pneumo-
coccal otitis media 41.4% [3]. While longer-term vaccine
effectiveness for all indications was assumed to be of at least 5
years’ duration [11], vaccine effectiveness was assumed to
decrease at a rate of 2% every 6 months; by age 5 years, the
effectiveness was assumed to have decreased by 18% [8].
Serotype Coverage and Serotype-Speciﬁc Efﬁcacy
The serotype coverage for infants and children in Turkey for 13-
valent PCV was taken to be 74%, for 10-valent PCV 61%, and for 7-
valent PCV 38% [9]. The serotype-speciﬁc age-speciﬁc vaccine
efﬁcacy for IPD reduces to 26% at 60 months for 7-valent PCV, to
42% for 10-valent PCV, and to 51% for 13-valent PCV.
Herd Protection
Not incorporated.
Cost of Disease Treatment
All the disease treatment costs are local costs (converted to 2011
US$). Only direct costs were applied. The cost of treating a
pediatric patient with pneumococcal bacteremia/septicemia wasociety for Pharmacoeconomics and Outcomes Research (ISPOR).
llege, Exhibition Road, London SW7 2AZ, UK.
Table 1 – Model inputs.
Input Source
Incidence of meningitis per
100,000
4 (up to 2 mo) (UK ¼ 11) [1] Local data [2]
5 (up to 24 mo) (UK ¼ 5–200) [1]
3 (up to 60 mo) (UK ¼ 20) [1]
Incidence of bacteremia/
septicemia per 100,000
7.5 (up to 2 mo) (UK ¼ 6.70) [1] Local data [2]
15 (up to 6 mo) (UK ¼ 5.80) [1]
22.5 (up to 24 mo) (UK ¼ 6–140) [1]
12.5 (up to 60 mo) (UK ¼ 3.50) [1]
Incidence of suspected
pneumococcal pneumonia
per 100,000
1,710 (up to 2 mo) (UK ¼ 4500) [1] Local data [2]
2,790 (up to 6 mo) (UK ¼ 880) [1]
2,290 (up to 12 mo) (UK ¼ 15,000) [1]
1,320 (up to 24 mo) (UK ¼ 1,300) [1]
210 (up to 60 mo) (UK ¼ 890–1,970) [1]
Incidence of all-cause otitis
media per 1,000
330 (up to 60 mo) (UK ¼ 23–62) [1] Local data [2]
Incidence of pneumococcal
otitis media per 1,000
58 (up to 60 mo) Prymula et al. [3]
IPD vaccine efﬁcacy 83% (7-valent PCV and 10-valent PCV) Black et al. [4]
83% (10-valent PCV) Palmu et al. [5]
Vaccine efﬁcacy against
suspected pneumococcal
pneumonia
20.5% (7-valent, 10-valent, and 13-valent PCV) Black et al. [6]
All-cause otitis media vaccine
efﬁcacy
6% (7-valent PCV and 13-valent PCV) Eskola et al. [7]
Pneumococcal otitis media
vaccine efﬁcacy
41.4% (10-valent PCV) Prymula et al. 2006 [3]
Reduction in vaccine
effectiveness over time
Decrease at a rate of 2% every 6 mo; reduced by 18% at 60 mo Extrapolated from Heath
et al. [8]
Serotype coverage 38% (7-valent), 61% (10-valent), 74% (13-valent) Erdem and Sener [9]
Costs In-hospital cost of treating meningitis US $1,000 (UK ¼ US $7,628) [1] National Burden of Disease
Study [10] and Turel et al.
[2]
In-hospital cost of treating bacteremia/septicemia US $500 (UK ¼ US
$4,254) [1]
In-hospital cost of treating suspected pneumococcal pneumonia US $40
(UK ¼ US $497) [1]
Cost of treating a case of otitis media US $30 (UK ¼ US $118) [1]
Following meningitis, cost of treating:
 deafness US $9,696 (UK ¼ US $96,960) [1]
 focal neurological deﬁcit US $2,4613 (UK ¼ US $24,230) [1]
 chronic seizures US $758 (UK ¼ US $7,592) [1]
Cost of a death US $160 (UK ¼ US $17,600) [1]
Mortality Average of 1,879 deaths per year (24 per 100,000 population younger
than age 5 y) of which 1,855 pneumonia-related and 24 IPD-related
National Burden of Disease
Study [10]
IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 5 5 – 7 5 9756US $500 and for pneumococcal meningitis, US $1000 [2]. The cost
of treating suspected pneumococcal pneumonia is made up of
7500 hospitalized cases at US $325 per case and 142,500 out-
patient cases at US $25 to US $60, with an average of US $40.50
per case [2]. The average cost of treating a case of pediatric otitis
media was US $30 [10].
Cost of Disease Sequelae
The long-term cost of treating deafness, focal neurological signs,
and chronic seizures following pneumococcal meningitis, occur-
ring at rates of 15.5% [12], 6% [13], and 7% [14] respectively, was
taken as one tenth the cost of treating such sequelae in the
United Kingdom [1] based on the relative per-capita gross
domestic products (GDPs) of Turkey and the United Kingdom,
and was on average US $1700 per child with long-term sequelae.
The cost of a death was US $160.Mortality
For pneumococcal meningitis, there would be 17 deaths in a total
of 555 cases, giving a case-fatality rate of 3.4% for those up to 24
months of age and 2.5% thereafter. For pneumococcal bacter-
emia/septicemia, there would be 7 deaths in a total of 264 cases,
giving a case-fatality rate of 2.6%. The number of deaths due to
suspected pneumococcal pneumonia is derived from the 13,253
deaths due to all causes reported in Turkey in the 7.794 million
infants and children younger than 5 years [15]. Of these deaths,
1855 (14%) are reported to be due to suspected pneumococcal
pneumonia. There would be a total of 150,020 cases of suspected
pneumococcal pneumonia, thus giving an average case-fatality
rate of 1.2%. This is lower than the pneumococcal pneumonia
case-fatality rate of 6% for the Eastern Mediterranean region as
reported in the Pneumococcal Global Burden of Disease study
[16]. There would be no deaths attributed to otitis media.
Table 2 – Results.
Cases averted
with 7-valent PCV
Cases averted with
10-valent PCV
Cases averted with
13-valent PCV
Cases occurring
if no vaccine
Cases (n)
Meningitis 124 199 241 552
Bacteremia or septicemia 549 882 1,070 2,333
Suspected pneumococcal pneumonia 21,278 21,278 21,278 149,506
All-cause otitis media 215,856 NA 215,856 5,070,068
Pneumococcal otitis media NA 262,427 NA 902,562
Lives saved 286 297 303
CLYG (US $) 7,109 6,784 6,696
Components of the incremental cost-
effectiveness ratio (ICER) (US $)
Total vaccine-related costs 160 million 160 million 160 million
Total disease-related costs (before
vaccination)
143 million 31.5 million 143 million
Total disease-related costs (with
vaccination)
136 million 23.0 million 135.5 million
Life-years gained 21,483 22,278 22,727
CLYG, cost per life-year gained; NA, not applicable/available; PCV, pneumococcal conjugate vaccine.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 5 5 – 7 5 9 757Discounting
Future health care costs were discounted at a rate of 3%.
Some models also discount future beneﬁts [17]. We performed a
sensitivity analysis with a 6% discounting of future beneﬁts.Vaccine Cost, Schedule, and Vaccination Coverage
The cost of each dose of vaccine was taken to be US $30 plus
an administration cost of US $3.26 for each dose, in a four-Table 3 – Sensitivity analysis (US $).
Parameter Chang
Base case
“Worst case” All changed to “lea
Pneumonia efﬁcacy Decrease to
Vaccine cost Increase by
Treatment costs Decrease b
Otitis media efﬁcacy Decrease 10-valent PC
Decrease 13-valent PC
Discount beneﬁts Increase t
Discount costs Increase t
Cases of meningitis Decrease b
Hospitalization rate for
pneumonia
Increase to
Hospitalization rate for
pneumonia
Decrease to
Cases of meningitis Increase by
Discount costs Decrease t
Incidence of bacteremia/
septicemia
Increase by
Otitis media efﬁcacy Increase 10-valent PCV efﬁcacy
OM
Increase 13-valent PCV efﬁcac
Treatment costs Increase by
Pneumonia efﬁcacy Increase to
Vaccine cost Decrease b
NA, not applicable/available; OM, otitis media; PCV, pneumococcal conjudose schedule and with 86% vaccine coverage in the
population.Cost-Effectiveness
A calculation of the mean cost of managing cases was performed
for a vaccinated and an unvaccinated population. The results
were expressed as cost per life-year gained and compared against
World Health organization cost-effectiveness thresholds of “verye 10-valent
PCV
13-valent
PCV
6,784 6,696
st favorable” 40,939 35,306
4.4% 23,583 22,197
50% 9,982 9,874
y 50% 6,980 6,866
V efﬁcacy to 6% 6,838 NA
V efﬁcacy to 3% NA 6,822
o 6% 7,419 6,952
o 6% 6,810 6,718
y 50% 6,866 6,790
7.5% 6,795 6,707
2.5% 6,747 6,659
50% 6,704 6,602
o 0% 6,754 6,670
50% 6,027 6,402
to 69.3% for pneumococcal 6,573 NA
y to 9% for all-cause OM NA 6,570
50% 6,587 6,526
34% 4,234 4,210
y 50% 3,586 3,517
gate vaccine.
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and “cost effective” being 3  per-capita GDP [18].
Sensitivity Analysis
Given that the model is a cohort model and not a Monte Carlo
simulation, we chose to perform a one-way sensitivity analysis
rather than a probabilistic sensitivity analysis.Results
The results are shown in Table 2. The base-case cost per life-
year gained would be US $7109, US $6784, and US $6696 for
7-valent, 10-valent, and 13-valent PCV, respectively. The cost of
a national immunization program using any of the vaccines
would be US $160 million. Using the World Health organization
threshold, the implementation of a universal state-funded
pediatric vaccination program using any PCV in Turkey is very
cost-effective.
Sensitivity Analysis
The sensitivity analysis is shown in Table 3. The vaccine efﬁcacy
against suspected pneumococcal pneumonia, based on that for
the Northern California Kaiser Permanente study [6], has the
greatest impact on the results. If the efﬁcacy of the vaccine was
only 4.4%, the lower end of the 95% conﬁdence interval, then the
vaccine would cease to be very cost-effective but would remain
cost-effective. Increasing the vaccine cost by 50% (to US $45) still
renders the vaccines very cost-effective. Changing all the para-
meters to the “least favorable” pushes the vaccines just beyond
the cost-effectiveness threshold.
The cost per life-year gained is below the 1  per-capita GDP
thresholds across large changes in key input parameters, indicat-
ing that the model is stable and suggesting that any PCV would
be very cost-effective in a Turkish national pediatric immuniza-
tion schedule.Discussion
The main ﬁnding of this analysis is that any PCV would appear to
be a very cost-effective intervention in the context of a national
pediatric immunization schedule in Turkey, even without
accounting for the added beneﬁts of herd protection and other
indirect effects such as societal savings. The main strengths of
the analysis reside in the inclusion of predominantly local data
and the use of an internationally recognized cost-effectiveness
yardstick.
There is an inherent weakness in the way the national ﬁgures
are derived in the present analysis in that the 12 Istanbul
hospitals may not be representative of hospitals in the wider
country and small inaccuracies in data at the 12 hospitals can be
magniﬁed into larger inaccuracies at a national level. The inclu-
sion of UK incidence rates and costs, as well as the sensitivity
analysis, provides a degree of conﬁdence that such inaccuracies,
if they exist, do not affect the results in a fundamental way.
The rates of pneumococcal infection used in the present
analysis are either comparable to or less than those calculated
and recently published for the Eastern Mediterranean Region [16].
The consequences for the present study are that the results are
likely to be more conservative than if a global estimate were to be
used, and the results reﬂect what may be monitored in Turkey
after the introduction of the vaccine.
For different regions of Turkey, the GINI coefﬁcient, a measure
of equality, suggests that within the different regions of Turkey
there is inequality, but that the inequality is distributed evenly[19]. We believe that the Turkish national data on health care and
the GINI coefﬁcients provide a degree of conﬁdence that our
results are applicable to Turkey as an entity. Although it is
difﬁcult to compare cost-effectiveness across different therapeu-
tic areas but using different measures, we have noted that
the cost per disability-adjusted life-year in Turkey for the treat-
ment of lung cancer is US $6141 and for hepatitis C treatment US
$6638. Treatment for these conditions in Turkey is funded by
the state.
A number of studies performed in countries with a socio-
economic background similar to that of Turkey also conclude that
PCV would be cost-effective using direct medical costs (Colombia
[20], Brazil [21], Taiwan [22], Malaysia [23], Argentina [24], and
Uruguay [25]) or even cost-saving with the inclusion of societal
costs (Mexico [26]).
In conclusion, it appears that any PCV, according to inter-
nationally accepted criteria, would be very cost-effective in a
national Turkish pediatric immunization schedule.
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